Search Results

Aptose Biosciences Inc. announced the voting results from the Company’s annual and special meeting of shareholders held today, June 18, 2024.

Aptose Biosciences Inc., a clinical-stage precision oncology company developing highly differentiated oral targeted agents to treat hematologic malignancies, announced financial results for the first quarter ended March 31, 2024.

Aptose Biosciences Inc. announced a clinical poster presentation and a preclinical e-poster at the European Hematology Association 2024 Hybrid Congress in Madrid, Spain.

Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), a clinical-stage precision oncology company developing highly differentiated oral targeted agents to treat hematologic malignancies, today announced financial results for the three months and year ended December 31, 2023, and provided a corporate update.

Aptose Biosciences Inc. today announced that it has entered into a definitive agreement for the issuance and sale of 3,855,000 of its common shares (or common share equivalents in lieu thereof) at a purchase price of $1.15 per share.

Aptose Biosciences Inc. announced the closing of its previously announced registered direct offering priced at-the-market under Nasdaq rules of 3,855,000 of its common shares at a purchase price of $1.15 per share.